Table 1.
Relationship between DLGAP5 immunoreactivity and clinicopathological findings in human prostate cancer (n = 95)
| DLGAP5 immunoreactivity | |||
|---|---|---|---|
| Negative (n = 91) | Positive (n = 4) | P‐value | |
| Age (y) | 67.9 ± 5.9 | 70.2 ± 3.8 | .45 |
| Gleason score | |||
| 5‐7 | 62 | 2 | .46 |
| 8‐10 | 29 | 2 | |
| Pathological T stage | |||
| 2 | 42 | 1 | .60 |
| 3a | 28 | 1 | |
| 3b | 19 | 1 | |
| 4 | 2 | 1 | |
| Pathological N stage | |||
| N0 | 73 | 3 | .80 |
| N1 | 18 | 1 | |
Immunoreactivity (IR) score (0‐8) was obtained as the sum of the proportion and the intensity of IR. Proportion (0, none; 1, <1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3; and 5, >2/3), Intensity (0, none; 1, weak; 2, moderate; and 3, strong). IR scores of 0‐4 and 5, 6 were defined as negative and positive IR, respectively.
Abbreviation: DLGAP5, disks large‐associated protein 5.